FDA grants marketing approval to scalp cooling system for breast cancer chemotherapy patients

The U.S. Food and Drug Administration (FDA) has cleared marketing of the Paxman Scalp Cooling System, a scalp cooling technology that was developed to reduce hair loss in breast cancer patients undergoing chemotherapy. The approval is based on the same…

from #Cancer-Sfakianakis via simeraentaxei on Inoreader http://ift.tt/2oDiSWV
via IFTTT Medicine by Alexandros G.Sfakianakis,Anapafseos 5 Agios Nikolaos,Crete 72100,Greece,tel :00302841026182 & 00306932607174

FDA grants marketing approval to scalp cooling system for breast cancer chemotherapy patients

Obesity behind surge in kidney cancers

An estimated 20,000 kidney cancer cases have been caused by obesity over the last decade in England, according to new figures from Cancer Research UK. Kidney cancer rates have increased by 40 per cent over the last 10 years in the UK, and the rise is…

from #Cancer-Sfakianakis via simeraentaxei on Inoreader http://ift.tt/2omCTVf
via IFTTT Medicine by Alexandros G.Sfakianakis,Anapafseos 5 Agios Nikolaos,Crete 72100,Greece,tel :00302841026182 & 00306932607174

Obesity behind surge in kidney cancers

Cancers, Vol. 9, Pages 39: Hepatocyte Growth Factor/c-Met Signaling in Head and Neck Cancer and Implications for Treatment

Aberrant signaling of the hepatocyte growth factor (HGF)/c-Met pathway has been identified as a promoter of tumorigenesis in several tumor types including head and neck squamous cell carcinoma (HNSCC). Despite a relatively low c-Met mutation frequency, overexpression of HGF and its receptor c-Met has been observed in more than 80% of HNSCC tumors, with preclinical and clinical studies linking overexpression with cellular proliferation, invasion, migration, and poor prognosis. c-Met is activated by HGF through a paracrine mechanism to promote cellular morphogenesis enabling cells to acquire mesenchymal phenotypes in part through the epithelial-mesenchymal transition, contributing to metastasis. The HGF/c-Met pathway may also act as a resistance mechanism against epidermal growth factor receptor (EGFR) inhibition in advanced HNSCC. Furthermore, with the identification of a biologically distinct subset of HNSCC tumors acquired from human papillomavirus (HPV) infection that generally portends a good prognosis, high expression of HGF or c-Met in HPV-negative tumors has been associated with worse prognosis. Dysregulated HGF/c-Met signaling results in an aggressive HNSCC phenotype which has led to clinical investigations for targeted inhibition of this pathway. In this review, HGF/c-Met signaling, pathway alterations, associations with clinical outcomes, and preclinical and clinical therapeutic strategies for targeting HGF/c-Met signaling in HNSCC are discussed.

from #Cancer-Sfakianakis via simeraentaxei on Inoreader http://ift.tt/2pWPmiB
via IFTTT Medicine by Alexandros G.Sfakianakis,Anapafseos 5 Agios Nikolaos,Crete 72100,Greece,tel :00302841026182 & 00306932607174

Cancers, Vol. 9, Pages 39: Hepatocyte Growth Factor/c-Met Signaling in Head and Neck Cancer and Implications for Treatment

Tumour Suppressors: Following the clues of cancer-resistant tissues

Using gene expression analyses of cancer-resistant differentiated muscle cells, Keckesova et al. identify a mitochondrial protein, lactamase β (LACTB), that affects lipid metabolism and can induce differentiation and suppress proliferation of breast cancer cells in vitro and in vivo.

from #Cancer-Sfakianakis via simeraentaxei on Inoreader http://ift.tt/2oD7SZh
via IFTTT Medicine by Alexandros G.Sfakianakis,Anapafseos 5 Agios Nikolaos,Crete 72100,Greece,tel :00302841026182 & 00306932607174

Tumour Suppressors: Following the clues of cancer-resistant tissues

New frontiers in translational control of the cancer genome

Nature Reviews Cancer16, 288–30410.1038/nrc.2016.27 (2016)In this Review, in Figure 1, for both the figure and figure legend ‘eIF4B’ was incorrectly labelled as ‘eIF2B’. The paper has been corrected online.

from #Cancer-Sfakianakis via simeraentaxei on Inoreader http://ift.tt/2oXBzqP
via IFTTT Medicine by Alexandros G.Sfakianakis,Anapafseos 5 Agios Nikolaos,Crete 72100,Greece,tel :00302841026182 & 00306932607174

New frontiers in translational control of the cancer genome

The challenge of targeting cancer stem cells to halt metastasis

Publication date: Available online 18 March 2017 Source:Seminars in Cancer Biology Author(s): Alice Agliano, Alfonso Calvo, Carol Box Despite a continuing debate about the existence of cancer stem cells (CSCs), recent discoveries have provided further support for their existence and their roles in drug resistance, cancer recurrence and metastasis. CSC characteristics, such as self-renewal and tumour initiation, and supporting cellular processes, particularly the epithelial-to-mesenchymal transition, are attracting a great deal of attention from cancer researchers as they offer opportunities for discovering novel therapeutic targets for future drug development. However, the identification of potential CSC targets presents clear obstacles due to a lack of truly specific CSC markers and the …

from #Cancer-Sfakianakis via simeraentaxei on Inoreader http://ift.tt/2pVUbWA
via IFTTT Medicine by Alexandros G.Sfakianakis,Anapafseos 5 Agios Nikolaos,Crete 72100,Greece,tel :00302841026182 & 00306932607174

The challenge of targeting cancer stem cells to halt metastasis